


In The ~~Claims~~

1. Bicyclic aromatic compounds,
characterized in that they correspond to the general
formula (I) below:





5 in which:

- R_1 represents (i) the $-CH_3$ radical
- (ii) the radical $-CH_2OR_5$,
- (iii) the radical $-COR_6$,

R_5 and R_6 having the meaning given below


10 - Ar represents a radical chosen from the radicals
of formulae (a) - (e) below:



R_5 and R_6 having the meaning given below,

00619584.071900

- X represents



or



R_2 and R_3 having the meanings given below

- R_2 and R_3 , which may be identical or different,
5 represent

(i) a hydrogen atom,

(ii) an alkyl radical having at least
3 carbon atoms, among which the carbon attached to the
phenyl radical is substituted with at least two carbon
10 atoms,

(iii) a radical $-OR_5$,

(iv) a radical $-SR_5$,

R_5 having the meaning given below,

it being understood that R_2 and R_3 , taken together,
15 may form with the adjacent aromatic ring a 5- or
6-membered ring optionally substituted with methyl
groups and/or optionally interrupted by an oxygen or
sulphur atom,

and it being understood that R_2 and R_3 cannot at
20 the same time have the meanings (i), (iii) and (iv)
mentioned above,

- R_4 and R_7 , which may be identical or different,
represent a hydrogen atom, a halogen atom, a linear or
branched alkyl radical having from 1 to 20 carbon atoms

00619584-071900

or a radical $-OR_5$,

- R_5 represents a hydrogen atom, a lower alkyl radical or a radical $-COR_{10}$

R_{10} having the meaning given below,

5 - R_6 represents:

- (a) a hydrogen atom
- (b) a lower alkyl radical
- (c) a radical of formula:



R' and R'' having the meaning given below,

10 (d) a radical $-OR_{11}$

R_{11} having the meaning given below,

- R_8 and R_9 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R_{10} represents a lower alkyl radical,

15 - R_{11} represents a hydrogen atom, a linear or branched alkyl radical having from 1 to 20 carbon atoms, an alkenyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl or aralkyl radical, a sugar residue or an amino acid or peptide residue,

20

- R' and R'' , which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, an optionally substituted aryl radical or an amino acid or sugar

00619584-071900

residue, or alternatively, taken together form a heterocycle,

as well as the salts thereof and the optical and geometrical isomers thereof.

5 2. Compounds according to Claim 1, characterized in that they are in the form of salts of an alkali metal or alkaline-earth metal, or alternatively of zinc or of an organic amine.

10 3. Compounds according to Claim 1, characterized in that they are taken, alone or as mixtures, from the group consisting of:

- 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,

15 - 5-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-propionic acid,

- 2-(3-tert-Butyl-4-methoxyphenyl)-4-thiophene-acrylic acid,

- 4-(3-tert-Butyl-4-methoxyphenyl)-2-thiophene-acrylic acid,

20 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiopheneacrylic acid,

- 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropionic acid,

25 - 4-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-thiopheneacrylic acid,

- 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-thiophenepropionic acid,

006720" 48567960

- 00619584.071900
- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylpropionic acid,
 - N-Methyl-4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-pyrroleacrylic acid,
 - 5 - 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
 - N-Methyl-4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
 - 10 - 4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyrroleacrylic acid,
 - 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
 - 3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylpropionic acid,
 - 15 - 2-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
 - 2-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
 - 2-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
 - 20 - 2-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
 - 2-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
 - 25 - 3-(3-Methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
 - 3-(3-Propyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,

- 3-(3-Heptyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(3-Methoxymethoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 5 - 3-(3-Hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,
- 3-(4,4,7-Trimethylthiochroman-6-yl)-phenylacrylic acid,
- N-Ethyl-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
- 10 - N-(4-Hydroxyphenyl)-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylamide,
- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid morpholide,
- 15 - Ethyl 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylate,
- 3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,
- 4-Methoxymethoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 20 - 4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 4-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 25 - 4-Propyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,
- 4-Heptyloxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,

09619584-071900

- 3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]acrolein,

- 3-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]prop-2-en-1-ol,

5 - cis-3-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenyl]but-2-enoic acid,

- cis-3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)phenylacrylic acid,

10 - 5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-pyridineacrylic acid,

- 3-(3-Butyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)phenylacrylic acid,


- 6-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-2-pyridineacrylic acid.

15 4. Compounds according to Claim 1, characterized in that they have at least one, and preferably all, of the following characteristics:

- R_1 represents the radical $-COR_2$,
- Ar represents the radicals of formula

20 (a) or (d)

- X represents the radical



- R_2 and R_3 , taken together, form, with the adjacent aromatic ring, a 5- or 6-membered ring optionally substituted with methyl groups and/or

optionally interrupted by an oxygen or sulphur atom.

5. Compounds according to any one of the preceding claims, for use as a medicinal product.

6. Compounds according to Claim 5, for use
5 as a medicinal product intended for the treatment of dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation, in particular for treating common acne, comedones, polymorphonuclear-
10 leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne and secondary acnes such as solar, medication-related or profession-related acne; for treating other types of keratinization disorder, in particular ichthyosis, ichthyosiform states, Darier's
15 disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous or mucous (buccal) lichen; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component and, in
20 particular, all forms of psoriasis, whether it is cutaneous, mucous or ungual psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy; the compounds may also be used
25 for some inflammatory complaints which show no keratinization disorder; for treating all dermal or epidermal hyperproliferations, whether benign or malignant and whether they are of viral origin or

00619584-071900

otherwise, such as common warts, flat warts and verruciform epidermodysplasia, it being possible for the oral or florid papillomatoses and the hyperproliferations to be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma; for treating other dermatological disorders such as bullosis and collagen diseases; for treating certain ophthalmological disorders, in particular corneopathies; for repairing or combating ageing of the skin, whether this is light-induced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing; for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for preventing or treating cicatrization disorders or for preventing or repairing vibices; for favouring cicatrization, for combating disorders of sebaceous functioning such as the hyperseborrhoea of acne or simple seborrhoea; in the treatment or prevention of cancerous or precancerous states, more particularly promyelocytary leukemia; in the treatment of inflammatory complaints such as arthritis; in the treatment of any general or skin complaint of viral origin; in the prevention or treatment of alopecia; in the treatment of dermatological complaints having an immunological component; in the treatment of complaints

00619584 071900

of the cardiovascular system such as arteriosclerosis or hypertension, as well as insulin-independent diabetes, in the treatment of skin disorders caused by exposure to UV radiation.

5 7. Pharmaceutical composition, characterized in that it comprises, in a pharmaceutically acceptable support, at least one of the compounds as defined in any of Claims 1 to 4.

10 8. Composition according to Claim 7, characterized in that the concentration of compound(s) according to one of Claims 1 to 4 is between 0.001% and 5% by weight relative to the composition as a whole.

15 9. Cosmetic composition, characterized in that it comprises, in a cosmetically acceptable support, at least one of the compounds as defined in any one of Claims 1 to 4.

20 10. Composition according to Claim 9, characterized in that the concentration of compound(s) according to one of Claims 1 to 4 is between 0.001% and 3% by weight relative to the composition as a whole.

11. Use of a cosmetic composition as defined in either of Claims 9 and 10, for body or hair hygiene.

add
PS1

006720-42567960